Pharmacological Smoking Cessation Aides And Cardiovascular Safety

Pharmacological smoking cessation therapies have had their challenges. For example, varenicline previously had a US Food and Drug Administration black box warning regarding neuropsychiatric risks. The EAGLES study, published 2016, was an industry sponsored, randomized, placebo-controlled trial of nicotine, varenicline, and bupropion that sought to address the neuropsychiatric risk profile of these medications.1 They randomized … Read more

It’s Electric!

As this crowd knows, cardiovascular disease is the leading cause of death worldwide, and though we’ve made great advancements to reduce morbidity and mortality in these patients, there is a desperate search for innovative new treatment strategies.   Traditionally, most chronic conditions are addressed with small molecule-based drugs that bind to their molecular target, exert … Read more